Erythema Migrans | Cytokines and Chemokines in Erythema Migrans
Erythema Migrans research study
What is the primary objective of this study?
The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.
Who is eligible to participate?
Inclusion Criteria: - erythema migrans in patients > 18 years Exclusion Criteria: - pregnancy or lactation - taking antibiotic with antiborrelial activity within 10 days
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:antibiotic treatmentPatient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
erythema migrans patients treated with antibioticsadult patients with erythema migrans will be treated with oral antibiotics
Start Date: July 2013
Completed Date: December 31, 2020
Primary Outcome: inflammatory proteins in erythema migrans patients
Secondary Outcome: gene polymorphisms in erythema migrans patients
Study sponsors, principal investigator, and references
Principal Investigator: Franc Strle, MD, PhD
Lead Sponsor: University Medical Centre Ljubljana
Collaborator: University of Ljubljana School of Medicine, Slovenia